JAMA· 2012Q1· Clinical trial
Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants
- 557citations
- Q1SCImago
- 2012year
Short summary
Autologous mesenchymal stem cells (MSCs) used as induction therapy in kidney transplants significantly reduced acute rejection rates and opportunistic infections compared to standard antibody induction, while also improving early renal function.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine